Navigation Links
Gene signature assesses breast cancer outcomes

A test that looks at the expression of 70 genes linked to breast cancer can accurately assess a patient's risk of recurrence or death, according to an article in the September 6 issue of the Journal of the National Cancer Institute.

In previous research, scientists at the Netherlands Cancer Institute in Amsterdam identified 231 genes associated with patient outcomes in a group of patients 55 years or younger with breast tumors under 5 cm. The 231 genes were reduced to a core group of 70 that make up a genetic signature to predict outcomes in a separate group of patients from the same institution.

To determine whether the 70-gene signature performed better than traditional risk classifiers, scientists from the international consortium TRANSBIG assigned 307 patients to high- and low-risk groups based on scores from the 70-gene signature and on traditional risk assessment with the Adjuvant Online! software. The patients were followed for 13.6 years and assessed for disease recurrence and death.

The authors found that the 70-gene signature was a more accurate predictor of disease outcomes than assessment with the Adjuvant Online! software. Moreover, statistical analysis indicated that most of the prognostic information provided by traditional risk classifiers was included in the gene classifier.

The authors write, "These results indicate that the gene signature adds independent prognostic information to that provided by a risk assessment based solely on clinico-pathologic factors."

In an accompanying editorial, Richard Simon, D.Sc., of the National Cancer Institute in Rockville, Md., discusses the strengths and limitations of the study by Buyse et al. He suggests improvements that might have been made in the study's design, and writes that the research, "Illustrate[s] many desirable features of gene expression profiling studies for optimizing treatment selection for individual patients."

The 70-gene signature will be pros pectively tested in a larger study called MINDACT, a trial coordinated by the European Organization for Research and Treatment of Cancer. This trial will assess whether the 70-gene signature can better identify who can safely be spared adjuvant chemotherapy in 6000 women with node-negative early-stage breast cancer. If validated, the tool could safely spare 1 in 6 women the burden of adjuvant chemotherapy.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Bioelectronic ‘signatures?hold key to DNA mutations
2. Eleven gene signature reliably predicts cancer prognosis
3. Common molecular signature identified in solid tumors
4. Novel molecular signature marks DNA of embryonic stem cells
5. Common molecular signature identified in solid tumors
6. Scientists use gene signatures to match cancer and other diseases with potentially effective drugs
7. Molecular signature protects cells from viruses
8. Molecular signature may identify cisplatin-sensitive breast tumors
9. Beyond the DNA: Chemical signatures reveal genetic switches in the genome
10. UCLA study assesses cost-effectiveness of Hepatitis B drugs
11. Viral DNA sequence a possible trigger for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... WonderWorks, Myrtle ... to showcase the future of deep space exploration and inspire space enthusiasts. The ... spacecraft and includes a guest appearance by former Shuttle Astronaut Don Thomas. , ...
(Date:4/26/2017)... Hong Kong (PRWEB) , ... April 26, 2017 ... ... be hosted in EMEA and North America this May ... from May 16-18 , Donald H. Taylor, Chairman of the Learning and Performance ...
(Date:4/25/2017)... ... 2017 , ... Franz Inc ., an early innovator ... market leader for Semantic Graph Database technology, today announced Allegro ... effective system for developing and deploying applications to solve the challenges developers face ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Metrology Partners.     , Covalent’s Analytical Services unit provides high-quality data to ... measured within 24 hours of receipt. There are no price premiums, and customers ...
Breaking Biology Technology: